Algeta Asa Is An Oncology Company Based In Oslonorwayfounded In 1997Originally Named Anticancer Therapeutic Inventions Asit Rebranded To Algeta Asa In 2003The Company Specializes In Developing Targeted Therapies For Cancer Patientsutilizing Its Alpha Pharmaceutical Platform Algeta S Main Product Is Xofigoradium 223 Dichloride A Targeted Alpha Pharmaceutical Approved By The Us Fda And European Ema For Treating Symptomatic Bone Metastases In Patients With Castration Resistant Prostate Cancerthe Company Is Also Working On Thorium 227An Alpha Emitter In The Preclinical Phaseaimed At Creating Targeted Thorium Conjugates Linked To Tumor Targeting Molecules Algeta Has A Notable Partnership With Bayer Pharma Ag For The Global Development And Commercialization Of Radium 223 Dichloridein 2014Algeta Was Acquired By Bayer For Approximately $2 9 Billionand It Now Operates As A Subsidiary Within Bayer S Portfolio
No conferences found for this company.
| Company Name | Algeta As |
| Country |
Norway
|
| Address | N/A |
| Telephone | N/A |
| N/A |
